The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Archives of Internal Medicine

Volumn 157, Issue 21, 1997, Pages 2413-2446

  Roccella, Edward J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CLINICAL PROTOCOL; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH PROGRAM; HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030713021     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.21.2413     Document Type: Review

References (254)

1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
2. National Heart, Lung, and Blood Institute staff. Calculated data. Cutler J, principal investigator. Bethesda, Md: National Heart, Lung, and Blood Institute; January 1997. [Unpublished data]
3. Manton KG, Corder L, Stallard E. Chronic disability trends in elderly United States populations: 1982-1994. Proc Natl Acad Sci USA. 1997;94:2593-2598.
4. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183. Pr
5. National Heart, Lung, and Blood Institute. Fact Book Fiscal Year 1996. Bethesda, Md: US Dept of Health and Human Services, National Institutes of Health; 1997.
6. U. S. Renal Data System. USRDS 1997Annual Report. Bethesda, Md: US Dept of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease; 1997. X
7. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562. F
8. National Center for Health Statistics, Health, United States, 1996. Hyattsville, Md: US Public Health Service; 1997.
9. Luepker RV, McGovern PG, Sprafka JM, Shahar E, Doliszny KM, Blackburn H. Unfavorable trends in the detection and treatment of hypertension: the Minnesota Heart Survey. Circulation. 1995;91:938. Abstract.
10. Meissner I, Whisnant JP, Sheps S, et al. Stroke prevention: assessment of risk in a community: the SPARC Study, 1: blood pressure trends, treatment, and control. Ann Neurol. 1997;42:433. Abstract.
11. Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke Incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373-380.
12. Glynn RJ, Brock DB, Harris T, et al. Use of antihypertensive drugs and trends in blood pressure in the elderly. Arch Intern Med.1995;155:1855-1860.
13. US Department of Health and Human Services. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, DC: US Public Health Service; 1991. DHHS publication (PHS) 91-50213.
14. Hall WD, Ferrario CM, Moore MA, et al. Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci. 1997;313:195-206. Pr
15. Banks J. National Heart, Lung, and Blood Institute Marketing Research Study on the Formatting, Dissemination, and Use of Clinical Practice Guidelines: Executive Overview. Bethesda, Md: National Heart, Lung, and Blood Institute; 1995.
16. Delbecq AL, Van de Ven AH, Gustafon DH. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes. Glenview, III: Scott Foresman & Co; 1975.
17. Last JM, Abramson JH, eds. A Dictionary of Epidemiology. 3rd ed. New York, NY: Oxford University Press; 1995.
18. Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J Hypertens. 1995;13:571-579.
19. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, IX: a method for grading health care recommendations. JAMA. 1995;274:1800-1804.
20. Zanchetti A, Mancla G, Editors' corner: strategies for antihypertensive treatment decisions: how to assess benefits? J Hypertens. 1997;15:215-216.
21. Chatellier G, Mènard J. The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. J Hypertens. 1997;15:217-219.
22. Linjer E, Hansson L. Underestimation of the true benefits of antihypertensive treatment: an assessment of some Important sources of error. J Hypertens 1997;15:221-225.
23. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens. 1996;10:1-8.
24. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313. X
25. Fuster V, Pearson TA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, September 14-15, 1995, J Am Coll Cardiol. 1996;27:957-1047.
26. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension. 1994;23:275-285. Pr
27. Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Arch intern Med 1992;152:56-64.
28. National High Blood Pressure Education Program. Churches as an Avenue to High Blood Pressure Control. Bethesda, Md: US Dept of Health and Human Services, National Heart, Lung, and Blood Institute; 1992. NIH publication 92-2725.
29. National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group Report on Primary Prevention of Hypertension. Bethesda, Md: US Dept of Health and Human Services, National Heart, Lung, and Blood Institute; 1993. NIH publication 93-2669. Pr
30. National Heart, Lung, and Blood Institute. Finding Resources for Healthy Heart Programs at Work. Bethesda, Md: US Dept of Health and Human Services, National Institutes of Health; 1992. NIH publication 92-737.
31. National Heart, Lung, and Blood Institute. Minority Health Issues for an Emerging Majority: 4th National Forum on Cardiovascular Health, Pulmonary Disorders, and Blood Resources Proceedings. Presented at a meeting sponsored by National Heart, Lung, and Blood Institute; NHLBI Ad Hoc Committee on Minority Populations; and National Medical Association; June 26-27, 1992; Washington, DC.
32. National Heart, Lung, and Blood Institute, The Sports Guide: NHLBI Planning Guide for Cardiovascular Risk Reduction Projects at Sporting Events. Bethesda, Md: US Dept of Health and Human Services, National Institutes of Health; 1995. NIH publication 95-3802.
33. University of Maryland School of Medicine. Control of Blood Pressure at the Workplace: University of Maryland School of Medicine. Baltimore: University of Maryland; 1982. NTIS accession PB83-113381.
34. Westinghouse Health Systems. Demonstration Programs in Hypertension Control in the Work Setting: Volume I: Technical Report. Columbia, Md: Westinghouse Health Systems; 1981. Contract NO1-HV-82911.
35. Westinghouse Health Systems. Demonstration Programs in Hypertension Control in the Work Setting: Volume II: Exhibits and Appendices. Columbia, Md: Westinghouse Health Systems; 1982. NTIS accession PB83-113373.
36. Erfurt JC, Foote A. Hypertension Control in the Work Setting: The University of Michigan Ford Motor Company Demonstration Program. Springfield, Va: National Technical Information Service; 1982. NTIS accession PB83-113399.
37. Hill MN, Bone LR, Butz AM, Enhancing the role of community-health workers in research. Image J Nurs Sch. 1996;28:221-226. Pr
38. Kotchen JM, McKean HE, Jackson-Thayer S, Moore RW, Straus R, Kotchen TA. Impact of a rural high blood pressure control program on hypertension control and cardiovascular disease mortality. JAMA. 1986;255:2177-2182.
39. Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health. 1983;73:153-162.
40. Stamler J. Blood pressure and high blood pressure: aspects of risk. Hypertension. 1991;18(suppl l):l-95-l-107. F
41. Flack JM, Neaton J, Grimm R Jr, et al, for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation. 1995;92:2437-2445.
42. Prisant LM, Alpert BS, Robbins CB, et al. American National Standard for nonautomated sphygmomanometers: summary report. Am J Hypertens. 1995;8:210-213.
43. Perloff D, Grim C, Flack J, et al. for the Writing Group. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88:2460-2467.
44. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens. 1992;5:207-209.
45. Pickering T, for an American Society of Hypertension ad hoc panel. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens. 1995;9:1-11. Pr
46. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet. 1997;349:454-457.
47. Appel LJ, Stason WB. Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and management of hypertension. Ann Intern Med. 1993;118:867-882.
48. Tsuji I, Imai Y, Nagai K, et al. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens. 1997;10:409-418.
49. O'Brien E, Petrie J, Littler W, et al. The British Hypertension Society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens. 1990;8:607-619.
50. White WB, Berson AS, Robbins C, et al. National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension. 1993;21:504-509.
51. Nesselroad JM, Flacco VA, Phillips DM, Kruse J. Accuracy of automated finger blood pressure devices. Fam Med. 1996;28:189-192.
52. Consumer Reports. Blood-pressure monitors: convenience doesn't equal accuracy. Consumer Rep. 1996;61:50, 53-55.
53. Sternberg H, Rosenthal T, Shamiss A, Green M, Altered circadian rhythm of blood pressure in shift workers. J Hum Hypertens. 1995;9:349-353.
54. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792-2798.
55. Perloff D, Sokolow M, Cowan RM, Juster RP. Prognostic value of ambulatory blood pressure measurements: further analyses. J Hypertens. 1989;7(suppl 3):S3-S10.
56. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
57. Klein R, Klein BEK, Moss SE, Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. Arch Ophthalmol. 1994;112:92-98.
58. Newman AB, Sutton-Tyrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993;270:487-489.
59. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management New York, NY: Raven Press; 1990:81-100.
60. Lifton RP, Dluhy RG, Powers M, et al. Achimaeric 11β-hydroxylase/aidosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
61. Lander ES, Schork NJ. Genetic dissection of complex traits. Science. 1994;265:2037-2048.
62. WHO Expert Committee on Hypertension Control. Hypertension Control: Report of a WHO Expert Committee. Geneva, Switzerland: World Health Organization; 1996. WHO Technical Report Series No. 862.
63. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
64. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-1576. F
65. Levy D. A multifactoral approach to coronary disease risk assessment. Clin Exp Hypertens. 1993;15:1077-1086.
66. American Heart Association. Welcome to the Coronary Heart Disease Risk Assessment. Available at: http://www.amhrt.org/risk/index.html.
67. Thürmer HL, Lund-Larsen PG, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? results from a prospective study. J Hypertens. 1994;12:481-490. F
68. Stamler R, Stamler J, Gosch FC, et al. Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial. JAMA. 1989;262:1801-1807. Ra
69. Stamler J, Caggiula AW, Grandits GA. Chapter 12: relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997;65(suppl):338S-365S. F
70. Hypertension Prevention Trial Research Group, The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. Arch Intern Med. 1990;150:153-162. Ra
71. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic Interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, phase I. JAMA. 1992;267:1213-1220. Ra
72. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157:657-667. Ra
73. Appel LJ, Moore TJ, Obarzanek E, et al, for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336;1117-1124. Ra
74. Du X, Cruickshank K, McNamee R, et al. Case-control study of stroke and the quality of hypertension control in northwest England. BMJ. 1997;314:272-276. Re
75. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-650. Ra, F
76. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med. 1997;157:99-104. F
77. Neaton JD,Grimm RH Jr, Prineas RJ, et al, for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study: final results. JAMA 1993;270:713-724. C, Ra
78. Singer DRJ, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension. 1995;25:1042-1044. Ra
79. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-468. X
80. Whelton PK, Applegate WB, Ettinger WH, et al. Efficacy of weight loss and reduced sodium intake in the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Circulation 1996;94(suppl 1):l-178. Abstract. Ra
81. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996. Pr
82. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997;337:581-588.
83. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616. Re
84. Puddey IB, Parker M, Beilen LJ, Vandongen R, Masarei JRL. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992;20:533-541. Ra
85. Gill JS, Shipley MJ, Tsementzis SA, et al. Alcohol consumption - a risk factor for hemorrhagic and non-hemorrhagic stroke. Am J Med. 1991;90:489-497. Re
86. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322:95-99. C
87. US Department of Agriculture and US Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans. 4th ed. Washington, DC: US Dept of Agriculture; 1995. Home and Garden Bulletin No. 232.
88. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med. 1993;328:538-545. F
89. Kokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 1995;333:1462-1467. Ra
90. Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1984;252:487-490. F
91. Weinberger MH, Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(pt2): 481-490. Pr
92. Elliott P, Stamler J, Nichols R, et al, for the Intersalt Cooperative Research Group. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ. 1996;312:1249-1253. X
93. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(suppl):643S-651S. M
94. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275:1590-1597. M
95. Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension. 1995;25:1144-1152. F
96. Devine A, Criddle RA, Dick IM, Kerr DA, Prince RL. A longitudinal study of the effect of sodium and calcium Intakes on regional bone density in postmenopausal women. Am J Clin Nutr. 1995;62:740-745. F
97. Ram CVS, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension: effects of potassium wastage and blood pressure control. Arch Intern Med. 1981;141:1015-1019. Ra
98. Antonios TFT, MacGregor GA. Salt - more adverse effects. Lancet. 1996;348:250-251. Pr
99. Cirillo M, Laurenzi M, Panarelli W, Stamler J, for the Gubbio Population Study Research Group. Urinary sodium to potassium ratio and urinary stone disease. Kidney Int. 1994;46:1133-1139. F
100. Liebson PR, Grandits GA, Dianzumba S, et al, for the Treatment of Hypertension Study Research Group. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698-706. Ra
101. Messerli FH, Schmieder RE, Weir MR. Salt: a perpetrator of hypertensive target organ disease? Arch Intern Med. 1997;157:2449-2452. Pr
102. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled clinical trials. JAMA. 1997;277:1624-1632. M
103. Cappuccio FP, Elliott P, Allender PS, Pryer J, Follman DA, Cutler JA. Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data. Am J Epidemiol. 1995;142:935-945. F
104. Allender PS, Cutler JA, Follmann D, Cappuccio FP, Pryer J, Elliott P. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med. 1996;124:825-831. M
105. Toft I, Bønaa KH, Ingebretsen OC, Nordøy A, Jenssen T. Effects of ω-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension: a randomized, controlled trial. Ann intern Med. 1995;123:911-918. Ra
106. Obarzanek E, Velletri PA, Cutler JA. Dietary protein and blood pressure. JAMA. 1996;275:1598-1603. Pr
107. Stamler J, Elliott P, Kesteloot H, et al. Inverse relation of dietary protein markers with blood pressure: findings for 10,020 men and women in the INTERSALT Study. Circulation. 1996;94:1629-1634. F
108. van Montfrans GA, Karemaker JM, Wieling W, Dunning AJ. Relaxation therapy and continuous ambulatory blood pressure in mild hypertension: a controlled study. BMJ. 1990;300:1368-1372. Ra
109. Alexander CN, Schneider RH, Staggers F, et al. Trial of stress reduction for hypertension in older African Americans, II: sex and risk subgroup analysis. Hypertension. 1996;28:228-237. Ra
110. Greenberg G, Thompson SG, Brennan PJ. The relationship between smoking and the response to antihypertensive treatment in mild hypertensives in the Medical Research Council's trial of treatment. Int J Epidemiol. 1987;16:25-30. F
111. US Department of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Rockville, Md: Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990. DHHS publication (CDC) 90-8416, Pr
112. Agency for Health Care Policy and Research. You Can Quit Smoking: Consumer Guide. Washington, DC: US Dept of Health and Human Services; 1996. AHCPR publication 96-0695.
113. American Heart Association. Calling It Quits. Dallas, Tex: American Heart Association; 1984.
114. American Lung Association. Helping Smokers Get Ready to Quit. New York, NY: American Lung Association; 1991.
115. US Department of Health and Human Services. 'I Quit' - What to Do When You're Sick of Smoking, Chewing, or Dipping. Atlanta, Ga: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1997.
116. Khoury Z, Comans P, Keren A, Lerer T, Gavish A, Tzivoni D. Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a double-blind study in healthy smokers. Cardiovasc Drugs Ther. 1996;10:179-184. Ra
117. Stamler J, Rains-Clearman D, Lenz-Litzow K, Tillotson JL, Grandits GA. Chapter 14: relation of smoking at baseline and during trial years 1-6 to food and nutrient intakes and weight in the special Intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997;65(suppl):374S-402S. F
118. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277:739-745. M
119. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials, J Am Coll Cardiol, 1996;27:1214-1218. Pr
120. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens. 1993;15:967-978. M
121. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461-1468. Ra
122. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med. 1996;156:1969-1978. Pr
123. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC, for the Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997;79:431-435. Ra
124. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331. Pr
125. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331. M
126. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens. 1997;15:105-115. Pr
127. Psaty BM, Furberg CD. Clinical Implications of the WHO/ISH statement on calcium antagonists. J Hypertens. 1997;15:1197-1200.
128. Gueyffier F, Boutitie F, Boissel JP, et al, for the INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997;126:761-767.M
129. Materson BJ, Reda DJ, Cushman WC, et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Singledrug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921. Ra
130. Grimm RH Jr, Grandits GA, Cutler JA, et al, for the TOMHS Research Group. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157:638-648. Ra
131. Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various Initial monotherapies for mild to moderate hypertension. JAMA. 1990;263:407-413. Pr
132. Jönsson BG. Cost-benefit of treating hypertension. J Hypertens. 1994;12(suppl 10):S65-S70. Pr
133. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics. 1995;7:242-250. Pr
134. Kaplan NM, Gifford RW Jr. Choice of initial therapy for hypertension. JAMA. 1996;275:1577-1580. Pr
135. Materson BJ, Reda DJ, Preston RA, et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Arch Intern Med. 1995;155:1757-1762. F
136. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495. Pr
137. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-1151. F
138. Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ. 1989;298:1552-1556. F
139. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the Incidence of myocardial infarction. Hypertension. 1994;23:395-401. F
140. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension - Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997;360:757-764. Ra
141. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298. Pr
142. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the Systolic Hypertension in the Elderly Program. Hypertension. 1993;21:335-343. Ra
143. Miller NH, Hill M, Kottke T, Ockene IS, The multilevel compliance challenge: recommendations for a call to action; a statement for healthcare professionals. Circulation. 1997;95:1085-1090. Pr
144. Schultz JF, Sheps SG. Management of patients with hypertension: a hypertension clinic model. Mayo Clin Proc 1994;69:997-999. Pr
145. Setaro JF, Black HR. Refractory hypertension. N Engl Med. 1992;327:543-547. Pr
146. US Bureau of the Census, Population Division. Estimates From the 1990 Census. Washington, DC: US Bureau of the Census; 1996. X
147. Fang J, Madhavan S, Alderman MH. The association between birthplace and mortality from cardiovascular causes among black and white residents of New York City. N Engl J Med 1996;335:1545-1551. F
148. Havas S, Sherwin R. Putting it all together: summary of the NHLBI Workshop on the Epidemiology of Hypertension in Hispanic American, Native American, and Asian/Pacific Islander American Populations. Public Health Rep. 1996;3(suppl 2):77-79. Pr
149. Chen MF, Chen CC, Chen WJ, Wu CC, Liau CS, Lee YT. Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension. Cardiovasc Drugs Ther. 1993;7;133-138. C
150. Chen MF, Yang CY, Chen WJ, et al. A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension. Cardiovasc Drugs Ther. 1995;9:401-406. X
151. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian In- dians to the United States of America. Indian Heart J. 1996;48:343-353. X
152. Howard BV, Lee ET, Yeh JL, et al. Hypertension in adult American Indians: the Strong Heart Study. Hypertension. 1996;28:256-264. X
153. Winkleby MA, Kraemer H, Lin J, Jatulis D, Fortmann SP, Sociodemographic influences on Hispanic-white differences in blood pressure. Public Health Rep. 1996;111(suppl 2):30-32. X
154. Singh GK, Kochanek KD, MacDorman MF. Advance report of final mortality statistics, 1994. Mon Vital Stat Rep. 1996;45(3, suppl):1-76. X
155. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277:1293-1298. F
156. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race-sex and blood pressure level: a further analysis. J Community Health. 1984;9:314-327. Ra
157. Ooi WL, Budner NS, Cohen H, Madhavan S, Alderman MH. Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension., 1989;14:227-234. F
158. 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990;48:665-675. Ra
159. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302. Ra
160. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics. 1996;98:649-658. Pr
161. Woods JW. Oral contraceptives and hypertension. Hypertension. 1988;11(suppl II):II-11-II-15. Pr
162. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996;335:257-265. Pr
163. Lindheimer MD. Pre-eclampsia - eclampsia 1996: preventable? have disputes on its treatment been resolved? Curr Opin Nephrol Hypertens. 1996;5:452-458. Pr
164. Levine RJ, for the CPEP Study Group. Calcium for preeclampsia (CPEP): a double-blind, placebo-controlled trial in healthy nulliparas. N Engl J Med. 1997;337:69-76. Pr
165. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. National High Blood Pressure Education Program working group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990;163:1689-1712. Pr
166. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208. Ra
167. Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med. 1993;329:1912-1917. F
168. Messerli FH. Osler's maneuver, pseudohypertension, and true hypertension in the elderly. Am J Med. 1986;80:906-910.
169. Wiinberg N, Høegholm A, Christensen HR, et al. 24-H ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995;8:978-986. X
170. Ooi WL, Barrett S, Hossain M, Kelley-Gagnon M, Lipsitz LA. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA. 1997;277:1299-1304. X
171. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264. Ra
172. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412. Ra, F
173. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285. Ra
174. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216. Ra
175. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587. C
176. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med. 1996;335:1660-1667. Pr
177. Smith SC Jr, Blair SN, Criqui MH, et al, for the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. J Am Coll Cardiol. 1995;26:292-294. Pr
178. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594-598. Re
179. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625. Re
180. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428. Pr
181. Gibson RS, Boden WE. Calcium channel antagonists: friend or foe in postinfarction patients? Am J Hypertens 1996;9:172S-176S. Pr
182. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann intern Med. 1991;114:345-352. F
183. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597. F
184. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation. 1997;95:1983-1985. Pr
185. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents: the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95:2007-2014. Ra
186. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793. F
187. Devereux RB, Agabiti-Rosei E, Dahlöf B, et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens. 1996;14(suppl 2):S95-S102. Pr
188. Frohlich ED. Pathophysiology of systemic arterial hypertension. In: Schlant RC, Alexander RW, O'Rourke RA, Roberts R, Sonnenblick EH, eds. Hurst's The Heart. 8th ed. New York, NY: Mc-Graw-Hill; 1993:1391-1401. Pr
189. Sheps SG, Frohlich ED. Limited echocardiography for hypertensive left ventricular hypertrophy. Hypertension. 1997;29:560-563. Pr
190. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. Arch Intern Med. 1996;156:1789-1796. Pr
191. Pfeffer MA, Braunwald E, Moyé LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trials. N Engl J Med. 1992;327:669-677. Ra
192. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456. M
193. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1542. Ra
194. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med. 1996;334:1349-1355. Ra
195. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375-380. Ra
196. Pitt B, Segal R, Martinez FA, et al, for the ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752. Ra
197. Packer M, O'Connor CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114. Ra
198. Cohn JN, Ziesche S, Smith R, et al, for the Vasodilator-Heart Failure Trial. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation. 1997;96:856-863. Ra
199. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034. Ra
200. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med. 1996;156:602-611. Pr
201. Fogo A, Smith MC, Cleveland W, Debruge J, Agodoa L, for the AASK Pilot Investigators. Renal biopsy findings in the African-American Study of Kidney Disease (AASK). J Am Soc Nephrol. 1994;5:560. Abstract. X
202. Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-594. F
203. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18. F
204. National High Blood Pressure Education Program Working Group. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch Intern Med. 1996;156:1938-1947. Pr
205. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997;29:744-750. Pr
206. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462. Ra
207. Klahr S, Levey AS, Beck GJ, et al, for the Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884. Ra
208. Maschio G, Alberti D, Janin G, et al, for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945. Ra
209. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann intern Med. 1997;127:337-345.
210. Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol. 1997;17:67-76. Pr
211. Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int. 1995;48:171-176. F
212. Vidt DG. Cholesterol emboli: a common cause of renal failure. Annu Rev Med. 1997;48:375-385. Pr
213. Bonelli FS, McKusick MA, Textor SC, et al. Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc. 1995;70:1041-1052. Re
214. Sos TA. Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation. 1991;83(suppl 1):1-162-1-166. Pr
215. Harden PN, MacLeod MJ, Rodger RSC, et al. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet. 1997;349:1133-1136. C
216. Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar ML, Strandness DE Jr. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens. 1996;9:1055-1061. F
217. American Diabetes Association. American Diabetes Association: clinical practice recommendations. Diabetes Care. 1997;20(suppl):S1-S70. Pr
218. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158. Pr
219. Curb JD, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892. Ra
220. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfo-nylureas. JAMA. 1997;278:40-43. Re
221. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289. Ra
222. Kasiske BL, Kalil BSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-138. M
223. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S, Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641-1650. Ra
224. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes, 1996;45:216-222. Ra
225. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381. Pr
226. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996;28:219-223. Pr
227. Working Group on Management of Patients With Hypertension and High Blood Cholesterol. National education programs working group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med. 1991;114:224-237. Pr
228. Kasiske BL, Ma JZ, Kalil RSN, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995:122:133-141. Pr
229. Stamler J, Briefel RR, Milas C, Grandits GA, Caggiula AW. Chapter 7: relation of changes in dietary lipids and weight, trial years 1-6, to changes in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997;65(suppl):272S-288S. F
230. Grimm RH Jr, Flack JM, Grandits GA, et al, for the Treatment of Mild Hypertension Study (TOMHS) Research Group. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA. 1996;275:1549-1556. Ra, F
231. Frost PH, Davis BR, Burlando AJ, et al, for the Systolic Hypertension in the Elderly Research Group. Serum lipids and incidence of coronary heart disease: findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation. 1996;94:2381-2388. F
232. Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. Adverse effects of antihypertensive medications in the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis. 1986;29(suppl1):73-88. F
233. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J. 1994;128:1177-1183. F
234. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial in- farction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371. M
235. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009. Ra
236. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307. Ra
237. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389. Ra
238. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321. M
239. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445. Pr
240. Hung J, Whitford EG, Parsons RW, Hillman DR. Association of sleep apnoea with myocardial infarction in men. Lancet. 1990;336:261-264. Re
241. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest. 1988;94:9-14. F
242. Sanders BP, Portman RJ, Ramey RA, Hill M, Strunk RC. Hypertension during reduction of long-term steroid therapy in young subjects with asthma. J Allergy Clin Immunol. 1992;89:816-821. F
243. Langford HG, Blaufox MD, Borhani NO, et al, for the Hypertension Detection and Follow-up Cooperative Group. Is thiazide-produced uric acid elevation harmful? analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med. 1987;147:645-649. F
244. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol. 1996;27:910-948. Pr
245. Riles TS, Fisher FS, Schaefer S, Pasternack PF, Baumann FG. Plasma catecholamine concentrations during abdominal aortic aneurysm surgery: the link to perioperative myocardial ischemia. Ann Vasc Surg. 1993;7:213-219.
246. Mangano DT, Layug EL, Wallace A, Tateo I, for the Multicenter Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996;335:1713-1720. Ra
247. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet. 1996;347:1061-1065. F
248. Zuccalá G, Pahor M, Landi F, et al. Use of calcium antagonists and need for perioperative transfusion in older patients with hip fracture: observational study. BMJ. 1997;314:643-644. C
249. Brecklin C, Gopaniuk A, Kravetz T, et al. Chronic cocaine abuse causes acute but not chronic hypertension. J Am Soc Nephrol. 1996;7:1547. Abstract.
250. Herzlich BC, Arsura EL, Pagala M, Grob D. Rhab-domyolysis related to cocaine abuse. Ann Intern Med. 1988;109:335-336.
251. Hollander JE, The management of cocaine- associated myocardial ischemia. N Engl J Med. 1995;333:1267-1272. X
252. Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897-803. Ra
253. Textor SC, Taler SJ, Canzanello VJ, Schwartz L. Cyclosporine, blood pressure and atherosclerosis. Cardiol Rev. 1997;5:141-151. Pr
254. Grossman E, Messerli FH. High blood pressure: a side effect of drugs, poisons, and food. Arch Intern Med. 1995;155:450-460.